A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints
- 1 June 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 13 (6), e240-e248
- https://doi.org/10.1016/s1470-2045(11)70378-3
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer SubtypeJournal of Clinical Oncology, 2011
- Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imagingEuropean Radiology, 2010
- Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI Journal of the National Cancer Institute, 2009
- Gene-Expression Signatures in Breast CancerNew England Journal of Medicine, 2009
- The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancerBreast Cancer Research and Treatment, 2009
- Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor CharacteristicsJNCI Journal of the National Cancer Institute, 2008
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences of the United States of America, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001